(NASDAQ: ARDX) Ardelyx's forecast annual revenue growth rate of 17.5% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.25%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.69%.
Ardelyx's revenue in 2025 is $398,234,000.On average, 14 Wall Street analysts forecast ARDX's revenue for 2025 to be $96,383,047,704, with the lowest ARDX revenue forecast at $87,281,230,201, and the highest ARDX revenue forecast at $104,323,448,024. On average, 14 Wall Street analysts forecast ARDX's revenue for 2026 to be $126,766,984,669, with the lowest ARDX revenue forecast at $93,824,528,262, and the highest ARDX revenue forecast at $143,848,078,381.
In 2027, ARDX is forecast to generate $156,944,393,475 in revenue, with the lowest revenue forecast at $111,469,322,364 and the highest revenue forecast at $194,658,865,252.